Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Bukwang confirmed Levovir showed tendency of reducing virus from Phase 2 clinical...

[May 12, 2021]

Bukwang Pharmaceutical Co., Ltd. announced the topline result of CLV-201, the Phase 2 clinical trial of Levovir as COVID-19 treatment. CLV-201 is randomized, placebo-controlled, single blinded Phase 2 study to evaluate the safety and efficacy of Levovir in patients diagnosed with moderate COVID-19. Study evaluated clinical efficacy and safety between 41 patients in the Levovir group and 20 patients in the placebo group. The study only enrolled the patients in the Negative Pressure Room at University Hospitall, not from the Residential Treatment Center....

R&D

Bukwang confirmed Levovir showed tendency of reducing virus from Phase 2 clinical trial topline...

[May 12, 2021]

Bukwang Pharmaceutical Co., Ltd. announced the topline result of CLV-201, the Phase 2 clinical trial of Levovir as COVID-19 treatment. CLV-201 is ran...

PRODUCTS
main_cg.jpg
COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...

|    ​Korean    |